Newly Published Study Finds VIVUS, Inc. (VVUS)'s Qsymia Achieves Greater Weight Loss at Lower Doses Than Either of Its Components as Monotherapy
10/31/2013 9:44:19 AM
MOUNTAIN VIEW, Calif., Oct. 31, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) announced today that a newly-published study demonstrated Qsymia® (phentermine and topiramate extended-release) capsules CIV produced significantly greater weight loss, and at lower doses, compared to phentermine or topiramate administered as monotherapies in obese adults. Among patients taking the once-daily extended-release formulation, Qsymia was generally well tolerated and improved blood pressure. In this study, the effect of Qsymia on heart rate was similar to placebo.
Help employers find you! Check out all the jobs and post your resume.
comments powered by